Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GHRS |
---|---|---|
09:32 ET | 1105 | 8.21 |
09:34 ET | 1895 | 8.265 |
09:36 ET | 10931 | 7.995 |
09:38 ET | 4267 | 8.1 |
09:39 ET | 100 | 7.91 |
09:43 ET | 2803 | 8.13 |
09:48 ET | 700 | 8 |
10:39 ET | 100 | 8.1483 |
10:55 ET | 100 | 8 |
11:27 ET | 100 | 7.925 |
11:45 ET | 100 | 7.93 |
11:47 ET | 200 | 7.93 |
11:56 ET | 100 | 7.93 |
11:58 ET | 100 | 7.93 |
12:03 ET | 100 | 8.0132 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
GH Research PLC | 415.7M | 0.0x | --- |
Instil Bio Inc | 429.9M | -3.6x | --- |
Larimar Therapeutics Inc | 437.1M | -6.6x | --- |
ACELYRIN Inc | 459.1M | -1.7x | --- |
Nkarta Inc | 371.8M | -2.8x | --- |
Northwest Biotherapeutics Inc | 384.5M | -4.8x | --- |
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $415.7M |
---|---|
Revenue (TTM) | --- |
Shares Outstanding | 52.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | --- |
Book Value | $4.21 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.